Opioids News and Research

RSS

An opioid is a chemical that works by binding to opioid receptors, which are found principally in the central nervous system and the gastrointestinal tract. The receptors in these two organ systems mediate both the beneficial effects and the side effects of opioids.

CLAAD urges FDA to implement Obama administration's policy on safer opioid medications

The Center for Lawful Access and Abuse Deterrence joined in signing a Citizen Petition filed today urging the Food and Drug Administration to fully implement the Obama administration's policy supporting a market transition to safer opioid medications.

11 Jun 2013

First consensus guidelines for use of neurostimulation in chronic pain

Recognizing that treatment of chronic pain can be confounding, the Neuromodulation Appropriateness Consensus Committee, an international group of more than 60 leading pain specialists, has created the first consensus guidelines for the use of neurostimulation in chronic pain.

10 Jun 2013

International experts formulate guidance for neuromodulation practitioners

An international panel of experts has formulated guidance for neuromodulation practitioners that reflects increasing recognition of the value of this growing field.

10 Jun 2013

Naloxegol meets primary and secondary endpoints in two pivotal Phase III studies

AstraZeneca today presented the results of two pivotal Phase III studies of naloxegol showing the 25 mg dose of the investigational drug met its primary and secondary endpoints for efficacy and showed a safety profile consistent with previous studies.

22 May 2013

COPD patients also experience significant amounts of chronic pain, researchers say

Chronic obstructive pulmonary disease is primarily associated with the respiratory symptoms that are its hallmark, but in fact, patients who struggle with the disease also experience significant amounts of chronic pain.

22 May 2013

PRIUM creates Centers with Standards database for payer-clients

PRIUM, a medical intervention company that helps reduce the inappropriate use of prescription drugs on workers' compensation claims, wants to highlight good functional restoration clinics and chronic pain management clinics for its payer-clients.

20 May 2013

FDA to review QRxPharma's resubmitted MOXDUO NDA in July 2013

QRxPharma Limited announced today the US Food and Drug Administration has set 17 July 2013 as the date of the Advisory Committee meeting to consider the Company's resubmitted MOXDUO New Drug Application.

18 May 2013

Regularly taking prescription painkillers is associated with higher risk of ED in men

Regularly taking prescription painkillers, also known as opioids, is associated with a higher risk of erectile dysfunction (ED) in men, according to a study published online today in the journal Spine.

17 May 2013

New challenges to military medicine

Better body armor and rapid aeromedical evacuations enable American service members to survive blasts that would have proved fatal in Vietnam or even the first Gulf War, but they pose new challenges to military medicine - how to deal with the excruciating pain of injuries, especially severe burns from IED blasts that body armor can't protect.

13 May 2013

Sedasys gets PMA approval from FDA for SEDASYS System

Sedasys, a Division of Ethicon Endo-Surgery, Inc., today announced that the U.S. Food and Drug Administration has granted PMA approval for the SEDASYS System, the first computer-assisted personalized sedation system.

5 May 2013

Martindale Pharma announces UK launch of Prenoxad Injection for opioid overdose

Martindale Pharma, a leader in the manufacture and supply of specialty pharmaceuticals, is pleased to announce the UK launch of Prenoxad Injection, the world's first licensed emergency treatment for acute opioid related overdose for use at home or other non-medical settings.

3 May 2013

Regional anesthesia improves outcomes in sleep apnea patients undergoing total joint arthroplasty

Using regional anesthesia instead of general anesthesia in patients with sleep apnea undergoing total joint replacement decreases major complications by 17%, according to a study published online, ahead of print, in the journal Regional Anesthesia and Pain Medicine.

3 May 2013

AcelRx Pharmaceuticals reports clinical results of Sufentanil NanoTab PCA System for acute pain treatment

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today reported additional clinical results for its lead product candidate, the Sufentanil NanoTab PCA System for the treatment of moderate-to-severe acute pain in the hospital setting.

2 May 2013

Maruishi gains exclusive rights to develop, commercialize Cara Therapeutics' CR845 in Japan

Cara Therapeutics, Inc. and Maruishi Pharmaceutical Company, Ltd. today announced that they have entered into a License Agreement providing Maruishi with exclusive rights to develop, manufacture and commercialize Cara's lead analgesic drug candidate, CR845, for acute pain and uremic pruritus in Japan.

29 Apr 2013

ORAEs increase costs of care, hospital stays and risks of readmission and mortality, research finds

Pacira Pharmaceuticals, Inc. today announced the publication of findings from a retrospective analysis of more than 37,000 patients who underwent common inpatient surgeries at a large, 26-hospital healthcare system and received opioids for postsurgical pain management.

25 Apr 2013

MOPHSF, UW Medicine Division of Pain Medicine team up to improve care for veterans

The Military Order of the Purple Heart Service Foundation and the UW Medicine Division of Pain Medicine are joining forces to assist veterans with treatment for Post-Traumatic Stress, Traumatic Brain Injury, and acute and chronic pain.

25 Apr 2013

Convergence starts Phase II proof of concept study with CNV2197944 in pain associated with PHN

Convergence Pharmaceuticals Limited, the company focused on the development of novel and high value analgesic medicines for the treatment of chronic pain, today announces that it has started a Phase II proof of concept study with CNV2197944 in pain associated with post-herpetic neuralgia.

24 Apr 2013

Sucampo's supplemental new drug application for AMITIZA gets FDA approval

Sucampo Pharmaceuticals, Inc. and Takeda Pharmaceuticals U.S.A., Inc. announced today that the United States Food and Drug Administration has approved Sucampo's supplemental new drug application for AMITIZA (lubiprostone) (24 mcg twice daily) as the first and only oral medication for the treatment of opioid-induced constipation in adult patients with chronic, non-cancer pain.

24 Apr 2013

1 in 4 teens misused or abused a prescription drug at least once in their lifetime

New, nationally projectable survey results released today by The Partnership at Drugfree.org and MetLife Foundation confirmed that one in four teens has misused or abused a prescription (Rx) drug at least once in their lifetime - a 33 percent increase over the past five years.

23 Apr 2013

Study indentifies unmet medical need for treatment of patients with chronic pain and dysphagia

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company focused on the development of innovative treatments for chronic pain, today announced the completion of a research study, conducted with an independent market research firm, that identified a significant unmet medical need for improved treatments for patients with chronic pain and dysphagia/odynophagia. In clinical practice, dysphagia is most often defined as difficulty in swallowing and odynophagia is defined as pain upon swallowing.

22 Apr 2013